Postoperative Wounds With Delayed Healing Risk of Clinical Trial Registration
NCT ID: NCT06272097
Last Updated: 2025-07-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
492 participants
INTERVENTIONAL
2025-12-31
2028-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Negative Pressure Wound Therapy vs. Conventional Dressings for Prevention of Wound Complications After Revision THA
NCT03321799
Routine Use of Negative Pressure Wound Therapy THR TKR RCT
NCT06181097
Improvement in Wound Healing With Negative Pressure Wound Therapy for Postoperative Total Hip Arthroplasty
NCT02355691
Closed Incision Negative Pressure Therapy vs Standard of Care
NCT03061903
Evaluating the Effectiveness of 2 Surgical Skin Preparation Methods in Reducing Surgical Wound Drainage After Total Hip or Knee Replacement
NCT01097135
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
2. Research Methods Study Design: This study employed a randomized controlled trial design, randomly assigning participants to an experimental group and a control group, which received different nursing management protocols.
Sample Size: A total of 492 patients are expected to be included, with 246 in the experimental group and 246 in the control group.
Intervention Measures: Patients in the experimental group will receive nursing management based on the TIME CDST tool, while those in the control group will receive conventional nursing management.
Evaluation Indicators: The primary outcome measure is wound healing time. Secondary outcome measures include the number of cases with wound healing, wound area reduction rate, ASEPSIS wound scoring system, Stone-Brock Scar Scoring Scale (SBSES), Visual Analog Scale (VAS), patient comfort score, patient satisfaction score, albumin levels, dressing change frequency, and medical costs.Clinical adverse events will be recorded for safety assessment.
Data collection and analysis: Data will be collected through questionnaire surveys, observation records, statistical analysis, and comparative analysis.
3. Study process Screening and grouping: Patients meeting the inclusion criteria will be screened and randomly assigned to the experimental group and control group.
Intervention Implementation: The experimental group will receive a nursing management plan based on the TIME CDST tool, while the control group will receive routine nursing management.
Follow-up and Evaluation: Regularly assess patients' wound conditions, record healing status, and collect patient satisfaction data.
Data Analysis: Analyze the collected data and compare differences between the experimental group and the control group in terms of various assessment indicators.
Result Interpretation and Report Writing: Based on the data analysis results, draw conclusions and write the research report.
4. Expected Results
Through the implementation of this study, the researchers expect to draw the following conclusions:
The nursing management plan based on the TIME CDST tool can significantly shorten the wound healing time after hip replacement surgery.
This plan can improve the wound healing rate after hip replacement surgery. This plan can enhance patient satisfaction with nursing services. This plan has practical application and promotion value in clinical practice.
5. Significance and Value of the Study This study holds significant importance and value for optimizing nursing management of wounds with delayed healing risk. Through scientific experimental design and rigorous data analysis, researchers can provide effective nursing management strategies for clinical practice, thereby improving patient outcomes and quality of life. Additionally, the findings of this study can serve as a reference and inspiration for other similar studies, contributing to the advancement and development of the nursing management field.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention group
The intervention group will receive an intervention plan based on the TIME CDST tool led by wound specialist nurses at each dressing change.
Intervention program based on TIME-CDST tool led by wound specialist nurses
Based on the TIME CDST tool led by wound specialist nurses, which includes the following five areas: A. Assess patient, well-being and wound; B. Bring in multidisciplinary team and informal carers to promote holistic patient care; C. Control or treat underlying causes and barriers to wound healing; D. Decide appropriate treatment; E. Evaluate and reassess the treatment and wound management outcomes; Give patients health education on wound care management.
Control group
The control group receives a routine wound care program of wound cleaning and dressing changes at each dressing change.
A routine wound care program
A routine wound care program of wound cleaning and dressing changes
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Intervention program based on TIME-CDST tool led by wound specialist nurses
Based on the TIME CDST tool led by wound specialist nurses, which includes the following five areas: A. Assess patient, well-being and wound; B. Bring in multidisciplinary team and informal carers to promote holistic patient care; C. Control or treat underlying causes and barriers to wound healing; D. Decide appropriate treatment; E. Evaluate and reassess the treatment and wound management outcomes; Give patients health education on wound care management.
A routine wound care program
A routine wound care program of wound cleaning and dressing changes
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* First-time recipient of unilateral total HA or hemiarthroplasty;
* Postoperative wound healing delay risk, defined as epithelialization \<50% at 2 weeks postoperatively (quantified using a standardized manual planar measurement method: on day 14 postoperatively, a (quantified using a standardized manual planar measurement method: on day 14 postoperatively, a standardized transparent grid membrane with 1mm² graduations is placed vertically over the wound, and the wound perimeter and epithelialization boundary are marked with a surgical marker. boundary are marked with a surgical marker pen; the epithelialized area is defined as pink, non-exudative tissue completely covering the dermis); Normal cognitive and communication abilities;
* Ability to comply with relevant nursing measures;
* Voluntary participation in this trial
* Voluntary participation in this trial and signed informed consent form.
Exclusion Criteria
* Complete wound dehiscence (\>2 cm) or exposure of the prosthesis/bone cement, requiring emergency revision surgery;
* Severe vascular insufficiency (ABI \<0.5 cm);
* Severe acute and chronic chronic disease (ABI \<0.5 cm) insufficiency (ABI \<0.6, severe limb ischemia);
* Uncontrolled systemic conditions severely impairing healing potential: severe malnutrition or obesity (BMI≥ 40 kg/m² or≤ 16 kg/m² or serum albumin \<2.5 g/dL); Uncontrolled diabetes (HbA1c \>9% in the past 3 months); severe heart failure (NYHA IV); severe liver dysfunction (Child-Pugh C); severe renal failure requiring dialysis; active malignant tumors; immunosuppressive therapy (high-dose corticosteroids \>10 mg prednisolone); and dose corticosteroids \>10 mg prednisone equivalent/day, biologics, or immunosuppressive agents following transplantation).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Danni Feng
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Danni Feng
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Danni Feng
Role: PRINCIPAL_INVESTIGATOR
Tongji Hospital
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
201328
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.